Back to Cabozantinib

Cabozantinib

Showing 1 study arm with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	median follow-up [months]⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Loo Gan et al.	2023	Retrospective	Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium	10.1016/j.euo.2022.10.004	—	50	Missing	15.6	Kidney cancer	metastatic	Multi-target TKI	Cabozantinib	—	Missing	both	brain, lung, adrenal gland, bone, LN unspecified, other	soft tissue, other sites not specified	27.25	8	50	5	1	13	Missing	Missing	Missing	Treatment-rel.	—	—	3	any G3: 2 AEs, any G4: 1 AE	any G3: 2 pts, any G4: 1 pt	any G3: vasogenic edema, colitis, any G4: pneumonitis	unknown